NIJBAS
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5797
PRINT ISSN: 2992-6122

NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES (NIJBAS)

Volume 7 Issue 2 Page 83-89, 2026

https://doi.org/10.59298/NIJBAS/2026/7.2.8389

Artemisinin Resistance Mechanisms and Surveillance Strategies in Southeast Asian Plasmodium Falciparum Malaria

Arionget Jemima

Department of Pharmacoepidemeology Kampala International University Uganda
Email: jemima.arionget@studwc.kiu.ac.ug

ABSTRACT

Artemisinin-based combination therapies have remained the cornerstone of global malaria treatment for over two decades, achieving remarkable reductions in morbidity and mortality. However, the emergence and spread of artemisinin-resistant Plasmodium falciparum strains in Southeast Asia threatens to undermine these gains and poses substantial challenges to malaria elimination efforts worldwide. This review examined the molecular mechanisms underlying artemisinin resistance in Plasmodium falciparum, evaluated current surveillance strategies employed in Southeast Asia, and assessed the implications for treatment efficacy and public health responses. A comprehensive synthesis of peer-reviewed literature on artemisinin resistance mechanisms, genetic markers, clinical manifestations, and epidemiological surveillance approaches was conducted. Mutations in the Kelch propeller domain, particularly K13, constituted the primary genetic determinant of artemisinin resistance, mediating delayed parasite clearance through enhanced cellular stress responses and altered hemoglobin metabolism. Resistance had spread across the Greater Mekong Subregion with distinct geographical clustering patterns. Molecular surveillance utilizing polymerase chain reaction-based detection of resistance markers, coupled with therapeutic efficacy studies and in vitro susceptibility testing, provided essential data for treatment policy adaptation. The emergence of partner drug resistance threatened the efficacy of artemisinin-based combination therapy. Integrated molecular and clinical surveillance frameworks were essential for tracking resistance evolution, informing treatment guidelines, and supporting malaria elimination strategies in endemic regions.

Keywords: Artemisinin resistance, Plasmodium falciparum, K13 mutations, Molecular surveillance, Southeast Asia.

INTRODUCTION

Artemisinin derivatives represent a class of sesquiterpene lactone compounds originally isolated from Artemisia annua that have revolutionized malaria chemotherapy through their rapid parasiticidal activity and broad stage specificity against asexual blood stage parasites [1]. The endoperoxide bridge within the artemisinin molecular structure generates reactive oxygen species upon interaction with heme or ferrous iron, leading to oxidative damage of parasite proteins and membranes [2]. Artemisinins demonstrate exceptionally short plasma half-lives and achieve parasite clearance within hours of administration, characteristics that distinguish them from previous antimalarial drug classes [3]. The World Health Organization recommendation of artemisinin-based combination therapies as first-line treatment for uncomplicated Plasmodium falciparum malaria has contributed to substantial declines in global malaria burden [4], with artemisinin compounds serving as the most rapidly acting and efficacious antimalarial agents currently available.

The relationship between artemisinin exposure and parasite response has undergone significant transformation in Southeast Asia, where reduced susceptibility to artemisinin compounds was first documented along the Thailand-Cambodia border in the early 2000s [5]. Delayed parasite clearance following artemisinin treatment emerged as the initial clinical manifestation of resistance, characterized by persistence of parasitemia beyond 72 hours and extended parasite clearance half-lives exceeding five hours [6]. The spread of artemisinin-resistant parasites throughout the Greater Mekong Subregion, encompassing Cambodia, Thailand, Vietnam, Myanmar, and Laos, has demonstrated the capacity for resistance traits to disseminate across international borders and establish endemic transmission foci [7]. This geographical expansion of resistance phenotypes correlates with specific molecular markers and threatens the therapeutic efficacy of artemisinin-based combination therapies, potentially compromising malaria control and elimination initiatives across endemic regions [8]. The objective of this review is to critically examine the molecular mechanisms mediating artemisinin resistance in Plasmodium falciparum, evaluate the surveillance strategies implemented for resistance detection and monitoring in Southeast Asia, and assess the implications for treatment policy and malaria elimination programs.

Molecular Mechanisms of Artemisinin Resistance

The primary genetic determinant of artemisinin resistance in Plasmodium falciparum involves mutations within the Kelch repeat propeller domain encoded by the K13 gene located on chromosome 13 [9]. More than 200 nonsynonymous K13 mutations have been identified globally [10], with a subset of validated mutations including C580Y, R539T, I543T, and Y493H demonstrating consistent association with delayed parasite clearance phenotypes and reduced artemisinin susceptibility in clinical and laboratory settings [11]. The C580Y mutation predominates in Cambodia and Vietnam, whereas R539T shows higher prevalence in Myanmar and Thailand, suggesting independent evolutionary origins and subsequent geographical expansion of distinct resistant lineages [12]. These mutations alter the protein structure of the Kelch domain, a six-bladed beta propeller that functions in protein ubiquitination and cellular quality control pathways, thereby modifying parasite responses to artemisinin-induced oxidative stress [13].

The mechanism by which K13 mutations confer artemisinin resistance involves modulation of the parasite unfolded protein response and alterations in phosphatidylinositol 3 phosphate metabolism during the ring stage of parasite development [14]. Resistant parasites exhibit enhanced cellular quiescence and reduced metabolic activity during early ring stages when artemisinin exposure typically occurs, a phenomenon termed ring stage dormancy or growth retardation [15]. This transient growth arrest allows parasites to survive brief artemisinin exposure during standard treatment courses, subsequently resuming normal development after drug concentrations decline below therapeutic thresholds [15]. K13 mutant parasites demonstrate increased expression of unfolded protein response genes and antioxidant enzymes, enhanced proteasome activity, and reduced hemoglobin uptake during ring stages, collectively contributing to diminished artemisinin susceptibility [16]. The endoplasmic reticulum-associated degradation pathway appears central to resistance mechanisms, with K13 mutations affecting substrate recognition and processing through modified ubiquitin ligase complex function [17]. These molecular adaptations represent sophisticated cellular responses that balance survival under drug pressure with maintenance of essential metabolic functions required for parasite replication and transmission, illustrating the complex interplay between parasite stress responses and antimalarial drug action.

Genetic Epidemiology and Resistance Spread

The geographical distribution of artemisinin-resistant Plasmodium falciparum exhibits distinct spatial patterns reflecting both independent emergence events and subsequent regional transmission of resistant lineages [18]. Whole genome sequencing studies have revealed multiple independent origins of K13 mutations within the Greater Mekong Subregion, with genetic backgrounds showing limited overlap between different resistance foci [19]. The Thailand-Cambodia border region served as the initial epicenter for artemisinin resistance, subsequently spreading eastward through Cambodia and into Vietnam, while distinct resistant lineages emerged independently in Myanmar along the Thailand-Myanmar border [20]. Population genetic analyses demonstrate that resistant parasites share extended haplotype homozygosity surrounding K13 loci, indicating recent positive selection and clonal expansion of successful resistant genotypes under sustained artemisinin drug pressure [21].

Molecular epidemiological surveillance has documented alarming increases in K13 mutation prevalence across Southeast Asia, with some areas reporting mutation frequencies exceeding 80 percent of parasite isolates [22]. The KEL1/PLA1 artemisinin-resistant lineage originating from western Cambodia has demonstrated remarkable fitness and transmission success, spreading across multiple countries and displacing susceptible parasite populations [23]. Population bottlenecks resulting from intensive malaria control interventions may paradoxically facilitate resistance spread by reducing genetic diversity and allowing resistant clones to achieve regional dominance [24]. Migration patterns, cross-border population movements, and mobile populations, including forest workers and migrant

laborers, contribute substantially to parasite gene flow and resistance dissemination between endemic foci [25]. Concerns regarding the potential transcontinental spread of artemisinin resistance to Africa, where malaria burden remains highest globally, have intensified surveillance efforts and prompted investigation of parasite population connectivity between Asian and African continents [26].

The fitness costs associated with K13 mutations appear minimal under drug pressure, with resistant parasites maintaining competitive growth rates and transmission potential comparable to susceptible strains when artemisinin selection pressure persists [27]. However, some evidence suggests reduced fitness in drug-free environments, potentially offering opportunities for resistance reversal if artemisinin pressure diminishes [28]. The complex relationship between genetic background, K13 mutations, and resistance phenotypes indicates that additional genetic modifiers influence artemisinin susceptibility, with certain genetic contexts enhancing or suppressing resistance expression associated with specific K13 alleles [29], highlighting the multifactorial genetic architecture underlying clinically relevant artemisinin resistance in field parasite populations.

Clinical Manifestations and Therapeutic Implications

Artemisinin resistance manifests clinically through delayed parasite clearance following treatment with artemisinin-based combination therapies, operationally defined as parasite positivity on day three of treatment or parasite clearance half-lives exceeding five hours [6]. The clinical significance of artemisinin resistance depends critically on partner drug efficacy within combination therapies, with artemisinin resistance alone typically permitting eventual parasite clearance, albeit with delayed kinetics [30]. However, the concurrent emergence of partner drug resistance, particularly to piperaquine in dihydroartemisinin piperaquine combinations, has resulted in true combination therapy failures with high treatment failure rates exceeding 50 percent in some areas of Cambodia and Vietnam [31]. These combination therapy failures represent the most serious threat to malaria treatment efficacy, potentially returning therapeutic outcomes to pre-artertemisinin era levels and severely compromising malaria elimination prospects [32].

Treatment failure resulting from artemisinin and partner drug resistance leads to prolonged parasitemia, increased gametocyte carriage, and enhanced transmission potential, directly impacting malaria control effectiveness at population levels [33]. Patients with resistant infections experience delayed clinical recovery and face elevated risks of severe malaria development if treatment fails. The limited antimalarial drug arsenal and absence of novel compounds in advanced development pipelines constrain therapeutic alternatives when first-line artemisinin-based combination therapies fail [34]. Current responses to combination therapy failure include deployment of alternative artemisinin-based combinations with different partner drugs, triple combination therapies incorporating three antimalarial compounds, and, in some settings, reversion to non-artemisinin-based regimens despite their inferior efficacy profiles [35].

Pharmacokinetic considerations influence resistance impacts, with longer-acting partner drugs providing extended post-treatment prophylaxis that may partially compensate for reduced artemisinin efficacy [36]. However, prolonged partner drug exposure also intensifies selection pressure favoring resistance evolution to these compounds [37]. The optimization of treatment regimens, including extended artemisinin courses and higher partner drug doses, has been explored as a potential strategy to overcome resistance, though concerns regarding tolerability, adherence, and accelerated resistance emergence temper enthusiasm for these approaches [38]. Understanding resistance mechanisms provides opportunities for rational drug development and deployment strategies that exploit vulnerabilities in resistant parasites, emphasizing the critical importance of mechanistic research for informing treatment policy decisions in resistance-affected regions.

Surveillance Frameworks and Detection Methodologies

Comprehensive surveillance systems integrating molecular, clinical, and epidemiological data provide essential infrastructure for detecting, monitoring, and responding to artemisinin resistance [39]. Molecular surveillance employing polymerase chain reaction amplification and sequencing of K13 resistance markers from dried blood spots or whole blood samples enables high-throughput population screening and resistance prevalence estimation [40]. These molecular surveys identify resistance marker distribution, track temporal trends in mutation frequencies, and provide early warning of resistance emergence in new geographical areas [41]. Standardized protocols for sample collection, DNA extraction, and K13 genotyping facilitate data comparability across surveillance sites and national programs, supporting regional resistance monitoring networks throughout Southeast Asia [42].

Therapeutic efficacy studies following World Health Organization standardized protocols represent the gold standard for assessing clinical treatment outcomes and detecting combination therapy failures [43]. These prospective clinical trials enroll patients with uncomplicated malaria, administer standard artemisinin-based combination therapy regimens, and monitor parasitological and clinical responses over 42 to 63 days [43]. Day three parasite positivity rates serve as key indicators of artemisinin resistance, while treatment failure rates reflect

overall combination therapy efficacy, including partner drug performance [44]. In vitro susceptibility testing using ring stage survival assays quantifies artemisinin resistance phenotypes by measuring parasite survival following brief pulsed artemisinin exposure, providing functional validation of resistance that complements molecular marker data [45]. Ex vivo drug susceptibility testing on fresh parasite isolates offers additional phenotypic data, though technical complexity and requirement for fresh samples limit widespread implementation [46].

Integration of multiple surveillance modalities strengthens resistance monitoring through complementary data streams that capture different resistance dimensions [39]. Molecular surveillance provides high geographical coverage and temporal resolution but relies on validated genetic markers that may not capture all resistance mechanisms. Clinical efficacy studies offer definitive evidence of treatment outcomes but require substantial resources and provide limited geographical and temporal coverage. In vitro assays quantify resistance phenotypes but may not fully recapitulate in vivo resistance impacts. Surveillance system effectiveness depends on sustained implementation, quality assurance, timely data analysis and reporting, and crucially, linkage between surveillance findings and policy responses, including treatment guideline modifications, with successful surveillance programs demonstrating measurable impacts on malaria control outcomes through evidence-informed interventions targeting resistant parasite populations.

Future Directions and Research Priorities

Critical knowledge gaps persist regarding artemisinin resistance mechanisms, with an incomplete understanding of how K13 mutations mechanistically confer reduced drug susceptibility and what additional genetic or epigenetic factors modulate resistance phenotypes [47]. The discovery of K13-independent resistance mechanisms, while currently uncommon, raises concerns about surveillance strategies reliant solely on K13 genotyping potentially missing emerging resistance forms [48]. Research priorities include comprehensive characterization of cellular pathways affected by K13 mutations, identification of additional resistance determinants through genome-wide association studies and functional genetic screens, and elucidation of interactions between artemisinin resistance and partner drug resistance that drive combination therapy failures [49].

Surveillance innovations incorporating mobile health technologies, point-of-care molecular diagnostics, and genomic epidemiology approaches offer opportunities for enhanced resistance detection and monitoring [50]. Portable sequencing platforms enable field-based genomic surveillance, potentially accelerating data generation and reducing delays between sample collection and results reporting [51]. Machine learning algorithms applied to genomic and epidemiological datasets may identify novel resistance markers and predict resistance spread patterns, informing preemptive control responses [52]. Integration of parasite genetic data with human mobility patterns, vector ecology information, and intervention coverage data through geospatial modeling platforms could enhance understanding of resistance transmission dynamics and optimize targeting of control interventions.

The development of next-generation antimalarial compounds with novel mechanisms of action represents the ultimate solution to artemisinin resistance, though drug development timelines extending over decades underscore the necessity of preserving the efficacy of existing drugs through rational deployment and resistance containment [53]. Alternative strategies, including chemoprevention approaches, transmission blocking interventions targeting gametocytes, and accelerated malaria elimination to reduce parasite populations before resistance fully establishes, may complement drug development efforts [54]. International coordination through mechanisms such as the World Health Organization Global Malaria Programme and the Mekong Malaria Elimination Programme facilitates harmonized surveillance standards, data sharing, and coordinated responses essential for addressing resistance as a regional rather than solely national challenge [55], recognizing that parasite populations transcend political boundaries and require correspondingly integrated control strategies.

CONCLUSION

Artemisinin resistance in Plasmodium falciparum represents one of the most significant contemporary threats to global malaria control, with Southeast Asia serving as the epicenter for resistance emergence and spread. Mutations in the K13 gene constitute the primary molecular basis for artemisinin resistance, mediating delayed parasite clearance through alterations in cellular stress responses and metabolic quiescence during ring stage development. The geographical expansion of resistant parasites throughout the Greater Mekong Subregion, coupled with emerging partner drug resistance leading to artemisinin-based combination therapy failures, has created urgent challenges for treatment policy and malaria elimination programs. Integrated surveillance frameworks combining molecular marker detection, therapeutic efficacy monitoring, and in vitro susceptibility testing provide essential data for tracking resistance evolution and informing evidence-based responses. However, surveillance systems require sustained investment, quality assurance, and critically, effective linkage between surveillance findings and policy implementation to achieve meaningful public health impact. The future containment of artemisinin resistance depends on continued research elucidating resistance mechanisms, development of novel antimalarial compounds,

optimization of existing treatment regimens, and coordinated regional elimination efforts that reduce parasite populations and transmission intensity, thereby limiting opportunities for further resistance evolution and spread. National malaria control programs in Southeast Asia should prioritize implementation of integrated molecular and clinical surveillance systems with annual monitoring cycles, ensuring rapid translation of resistance data into treatment policy adaptations and targeted elimination interventions in high resistance prevalence areas

REFERENCES

1. Tu Y. Artemisinin—a gift from traditional Chinese medicine to the world (Nobel Lecture). Angew Chem Int Ed. 2016;55(35):10210–26. doi:10.1002/anie.201601967.
2. Bridgford JL, Xie SC, Cobbold SA, et al. Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome. Nat Commun. 2018;9(1):3801. doi:10.1038/s41467-018-06221-1.
3. Egwu, C.O., Aloke, C., Chukwu, J., Agwu, A., Tsamesidis, I, et al. A world free of malaria: It is time for Africa to actively champion and take leadership of elimination and eradication strategies. Afr Health Sci. 2022 Dec;22(4):627-640. doi: 10.4314/ahs.v22i4.68.
4. World Health Organization. World Malaria Report 2023. Geneva: WHO; 2023. Available from: https://www.who.int/publications/i/item/9789240086678.
5. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361(5):455–67. doi:10.1056/NEJMoa0808859.
6. World Health Organization. Artemisinin resistance and artemisinin-based combination therapy efficacy: status report. Geneva: WHO; 2018. Available from: https://www.who.int/publications/i/item/WHO-CDS-GMP-2018.18.
7. Amaratunga C, Lim P, Suon S, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016;16(3):357–65. doi:10.1016/S1473-3099(15)00487-9.
8. Tufail T, Agu PC, Akinloye DI, Obaroh IO. Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. Medicine, 2024; 103(49), e40241. doi: 10.1097/MD.0000000000040241. PMID: 39654176
9. Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505(7481):50–5. doi:10.1038/nature12876.
10. Roberto Amato, Olivo Miotto, Charles J Woodrow, Jacob Almagro-Garcia, Ipsita Sinha, et al.. Genomic epidemiology of artemisinin resistant malaria. eLife, 2016, 48 (8), pp.959-964. ⟨10.7554/eLife.08714⟩. ⟨pasteur-01971950⟩
11. Menard D, Khim N, Beghain J, et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016;374(25):2453–64. doi:10.1056/NEJMoa1513137.
12. Phyo AP, Ashley EA, Anderson TJC, et al. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003–2013): the role of parasite genetic factors. Clin Infect Dis. 2016;63(6):784–91. doi:10.1093/cid/ciw388.
13. Mbengue A, Bhattacharjee S, Pandharkar T, et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature. 2015;520(7549):683–7. doi:10.1038/nature14412.
14. Yang T, Yeoh LM, Tutor MV, et al. Decreased K13 abundance reduces hemoglobin catabolism and proteotoxic stress, underpinning artemisinin resistance. Cell Rep. 2019;29(9):2917–28.e5. doi:10.1016/j.celrep.2019.10.095.
15. Hott A, Tucker MS, Casandra D, et al. Fitness of artemisinin-resistant Plasmodium falciparum in vitro. J Antimicrob Chemother. 2015;70(10):2787–96. doi:10.1093/jac/dkv199.
16. Mok S, Ashley EA, Ferreira PE, et al. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science. 2015;347(6220):431–5. doi:10.1126/science.1260403.
17. Siddiqui FA, Liang X, Cui L. Plasmodium falciparum resistance to ACTs: emergence, mechanisms, and outlook. Int J Parasitol Drugs Drug Resist. 2021;16:102–18. doi:10.1016/j.ijpddr.2021.05.007.
18. Miotto O, Amato R, Ashley EA, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet. 2015;47(3):226–34. doi:10.1038/ng.3189.
19. Imwong M, Suwannasin K, Kunasol C, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infect Dis. 2017;17(5):491–7. doi:10.1016/S1473-3099(17)30048-8.
20. Tun KM, Imwong M, Lwin KM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15(4):415–21. doi:10.1016/S1473-3099(15)70032-0.

21. Cerqueira GC, Cheeseman IH, Schaffner SF, et al. Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance. Genome Biol. 2017;18(1):78. doi:10.1186/s13059-017-1204-4.
22. Imwong M, Dhorda M, Myo Tun K, et al. Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infect Dis. 2020;20(12):1470–80. doi:10.1016/S1473-3099(20)30228-0.
23. Dwivedi A, Khim N, Reynes C, et al. Plasmodium falciparum parasite population structure and gene flow associated to anti-malarial drugs resistance in Cambodia. Malar J. 2016;15:319. doi:10.1186/s12936-016-1370-y.
24. Boni MF, Smith DL, Laxminarayan R. Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci USA. 2008;105(37):14216–21. doi:10.1073/pnas.0804628105.
25. Peeters Grietens K, Gryseels C, Dierickx S, et al. Characterizing types of human mobility to inform differential and targeted malaria elimination strategies in Northeast Cambodia. Sci Rep. 2015;5:16837. doi:10.1038/srep16837.
26. Huang F, Takala-Harrison S, Jacob CG, et al. A single mutation in K13 predominates in Southern China and is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment. J Infect Dis. 2015;212(10):1629–35. doi:10.1093/infdis/jiv249.
27. Nair S, Li X, Arya GA, et al. Fitness costs and the rapid spread of Kelch13-C580Y substitutions conferring artemisinin resistance. Antimicrob Agents Chemother. 2018;62(3):e00605-17. doi:10.1128/AAC.00605-17.
28. Straimer J, Gnädig NF, Stokes BH, et al. Plasmodium falciparum K13 mutations differentially impact ozonide susceptibility and parasite fitness in vitro. mBio. 2017;8(2):e00172-17. doi:10.1128/mBio.00172-17.
29. Henriques G, Hallett RL, Beshir KB, et al. Directional selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu loci of Plasmodium falciparum in Kenyan children treated with ACT. J Infect Dis. 2014;210(12):2001–8. doi:10.1093/infdis/jiu358.
30. White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320(5874):330–4. doi:10.1126/science.1155165.
31. van der Pluijm RW, Imwong M, Chau NH, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019;19(9):952–61. doi:10.1016/S1473-3099(19)30391-3.
32. Menard D, Dondorp A. Antimalarial drug resistance: a threat to malaria elimination. Cold Spring Harb Perspect Med. 2017;7(7):a025619. doi:10.1101/cshperspect.a025619.
33. Slater HC, Griffin JT, Ghani AC, Okell LC. Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa. Malar J. 2016;15:10. doi:10.1186/s12936-015-1075-7.
34. Wells TNC, Hooft van Huijsduijnen R, Van Voorhis WC. Malaria medicines: a glass half full? Nat Rev Drug Discov. 2015;14(6):424–42. doi:10.1038/nrd4573.
35. van der Pluijm RW, Tripura R, Hoglund RM, et al. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet. 2020;395(10233):1345–60. doi:10.1016/S0140-6736(20)30552-3.
36. Hoglund RM, Workman L, Edstein MD, et al. Population pharmacokinetic properties of piperaquine in falciparum malaria: an individual participant data meta-analysis. PLoS Med. 2017;14(3):e1002212. doi:10.1371/journal.pmed.1002212.
37. Alum EU. Phytochemicals in Malaria Treatment: Mechanisms of Action and Clinical Efficacy. KIU J. Health Sci., 2024; 4(2):71-84. https://doi.org/10.59568/KJHS-2024-4-2-06.
38. Duru V, Witkowski B, Ménard D. Plasmodium falciparum resistance to artemisinin derivatives and piperaquine: a major challenge for malaria elimination in Cambodia. Am J Trop Med Hyg. 2016;95(6):1228–38. doi:10.4269/ajtmh.16-0234.
39. Ainebyoona C, Egwu CO, Onohuean H, Ugwu OPC, Uti DE, Echegu DA. Mitigation of Malaria in Sub-Saharan Africa through Vaccination: A Budding Road Map for Global Malaria Eradication (2025). Ethiopian Journal of Health Sciences, 2025; 35(3): 205-217. doi: 10.4314/ejhs.v35i3.9. PMID: 40717722; PMCID: PMC12287706

OPEN ACCESS
ONLINE ISSN: 2992-5797
PRINT ISSN: 2992-6122

40. Taylor SM, Parobek CM, Fairhurst RM. Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(6):457–68. doi:10.1016/S1473-3099(12)70055-5.
41. Talundzic E, Okello PE, Macklin MD, et al. Selection and spread of artemisinin-resistant Plasmodium falciparum in Guyana: a population genetics and molecular epidemiology study. Lancet Microbe. 2021;2(10):e569–77. doi:10.1016/S2666-5247(21)00117-8.
42. WHO Global Malaria Programme. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009.
43. World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva: WHO; 2018. Available from: https://www.who.int/publications/i/item/9789241597531.
44. Plucinski MM, Talundzic E, Morton L, et al. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, Angola. Antimicrob Agents Chemother. 2015;59(1):437–43. doi:10.1128/AAC.04181-14.
45. Witkowski B, Amaratunga C, Khim N, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis. 2013;13(12):1043–9. doi:10.1016/S1473-3099(13)70252-4.
46. Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev. 2017;41(1):34–48. doi:10.1093/femsre/fuw037.
47. Balikagala B, Fukuda N, Ikeda M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385(13):1163–71. doi:10.1056/NEJMoa2101746.
48. Miotto O, Sekihara M, Tachibana SI, et al. Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea. PLoS Pathog. 2020;16(12):e1009133. doi:10.1371/journal.ppat.1009133.
49. Mathieu LC, Cox H, Early AM, et al. Local emergence in Amazonia of Plasmodium falciparum k13 C580Y mutants associated with in vitro artemisinin resistance. eLife. 2020;9:e51015. doi:10.7554/eLife.51015.
50. Shetty AC, Jacob CG, Huang F, et al. Genomic structure and diversity of Plasmodium falciparum in Southeast Asia reveal recent parasite migration patterns. Nat Commun. 2019;10(1):2665. doi:10.1038/s41467-019-10121-3.
51. Oyola SO, Gu Y, Manske M, et al. Efficient depletion of host DNA contamination in malaria clinical sequencing. J Clin Microbiol. 2013;51(3):745–51. doi:10.1128/JCM.02507-12.
52. Mwai L, Diriye A, Masseno V, et al. Genome wide adaptations of Plasmodium falciparum in response to lumefantrine selective drug pressure. PLoS One. 2012;7(2):e31623. doi:10.1371/journal.pone.0031623.
53. Macintyre F, Adoke Y, Tiono AB, et al. A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria. BMC Med. 2017;15(1):181. doi:10.1186/s12916-017-0940-3.
54. Newby G, Hwang J, Koita K, et al. Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg. 2015;93(1):125–34. doi:10.4269/ajtmh.14-0254.
55. Roper C, Alifrangis M, Ariey F, et al. Molecular surveillance for artemisinin resistance in Africa. Lancet Infect Dis. 2014;14(8):668–70. doi:10.1016/S1473-3099(14)70826-6.

CITE AS: Arionget Jemima (2026). Artemisinin Resistance Mechanisms and Surveillance Strategies in Southeast Asian Plasmodium Falciparum Malaria. NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 7(2):83-89.
https://doi.org/10.59298/NIJBAS/2026/7.2.8389